Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial

Key Takeaways

• Ascletis Pharma has completed enrollment of 100 participants in its 13-week U.S. Phase II trial for ASC30, an oral GLP-1 receptor agonist
• ASC30 represents a potential breakthrough as a once-daily oral tablet alternative to injectable GLP-1 diabetes medications
• Topline efficacy and safety data from the Phase II study are expected in the third quarter of 2026

---

HONG KONG - Ascletis Pharma Inc. (HKEX: 1672) announced the completion of enrollment in its U.S. Phase II clinical trial evaluating ASC30, an investigational oral small molecule GLP-1 receptor agonist for diabetes treatment. The 13-week study (NCT07321678) has enrolled 100 participants and represents a significant milestone in developing oral alternatives to injectable diabetes medications.

Study Design and Objectives

The Phase II trial is designed to evaluate the efficacy, safety, and tolerability of ASC30 as a once-daily oral tablet. This approach could address a major limitation of current GLP-1 receptor agonists, which are typically administered via injection and may present barriers to patient compliance and convenience.

GLP-1 receptor agonists have become increasingly important in diabetes management due to their ability to improve blood sugar control while potentially offering weight loss benefits. However, the injectable nature of most current therapies has created demand for oral formulations that could improve patient adherence and quality of life.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Implications

The successful development of an oral GLP-1 receptor agonist could represent a significant competitive advantage in the rapidly growing diabetes therapeutics market. Current injectable GLP-1 medications have achieved substantial commercial success, but an effective oral alternative could capture significant market share by appealing to patients who prefer oral medications.

Ascletis’ progress with ASC30 positions the company to potentially compete with other pharmaceutical companies developing oral GLP-1 therapies. The completion of enrollment demonstrates the company’s ability to execute clinical trials and advances the program toward potential regulatory submissions.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Timeline and Next Steps

With enrollment now complete, Ascletis expects to report topline data from the Phase II study in the third quarter of 2026. These results will be critical in determining whether ASC30 demonstrates sufficient efficacy and safety to warrant advancement to Phase III trials, which would be required for regulatory approval.

The 13-week study duration should provide adequate time to assess both the therapeutic effects and safety profile of ASC30 in the enrolled patient population. Positive results could accelerate the development timeline and increase investor and partner interest in the program.

---

Frequently Asked Questions

What makes ASC30 different from existing diabetes medications?

ASC30 is an oral GLP-1 receptor agonist taken as a once-daily tablet, potentially offering the same benefits as injectable GLP-1 medications but with improved convenience and patient compliance.

When will ASC30 be available to patients?

ASC30 is still in Phase II trials with results expected in Q3 2026. If successful, the drug would need to complete Phase III trials and regulatory approval, likely taking several more years before market availability.

How does oral GLP-1 therapy compare to injectable options?

Oral GLP-1 medications could offer similar blood sugar control and weight management benefits as injections but with better patient acceptance and adherence due to the convenience of tablet administration.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
• MariTide Phase 2 obesity data show up to 20% weight loss at one year